As afatinib and DTX display considerable efficacy in treating advanced non-squamous NSCLC with EGFRwt, EGFR-targeted therapy with DTX is considered to have potential for NSCLC treatment [36]. Here, EGFR is linked to non-small cell lung carcinoma.